Cancer|Information,Research,Treatment,Alternative|GynCancerDoctor.com

Home arrow Cancer Research and News arrow Cancer General News arrow Cancer Research and Clinical Trials News arrow OVArian TUmor REsponse (OVATURE) Study: A Promising New Strategy
 
OVArian TUmor REsponse (OVATURE) Study: A Promising New Strategy PDF Print E-mail
Monday, 28 January 2008
Initially, ovarian Cancer cells are usually very sensitive to chemotherapy. Unfortunately, at some point in time they lose sensitivity and develop "chemo-resistance", making successful treatment all but impossible.

Phenoxodiol, a synthetic variant of naturally occurring isoflavones found in multiple plants, has demonstrated an ability to kill cancer cells that are relatively resistant to standard chemotherapy drugs both in laboratory studies and in early phase clinical trials.  It has also been shown to restore the sensitivity of “chemo-resistant” cancer cells to carboplatin in laboratory studies. This is important because carboplatin is one of the main chemotherapy drugs used for ovarian cancer treatment.

Currently, based on exciting early phase trial results, an international Phase III randomized clinical trial is underway which compares carboplatin with or without phenoxodiol in chemo-resistant ovarian cancer. You can read more about it to see if you qualify and to determine if one of the OVATURE clinical trial investigation sites is near you.




Reddit!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Newsvine!Furl!Yahoo!Ma.gnolia!Free social bookmarking plugins and extensions for Joomla! websites!
Last Updated ( Saturday, 16 February 2008 )
 
Next >